Sectors
MLTX
MoonLake Immunotherapeutics
14.88
1 x 14.76
2 x 19.31
bid
ask
-
0.11
0.73%
03:05 PM
timesize
| Ytd | 12.90% | |
| 1y | -73.31% |
14.63
day range
14.96
5.95
52 week range
62.75
| Open | 14.94 | Prev Close | 14.99 | Low | 14.63 | High | 14.96 | Mkt Cap | 1.27B |
| Vol | 579.10K | Avg Vol | 1.24M | EPS | -3.84 | P/E | N/A | Forward P/E | -4.49 |
| Beta | 1.06 | Short Ratio | 5.61 | Inst. Own | 87.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 18.36 | 200-d Avg | 16.84 | 1yr Est | 28.54 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.77 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.91 | -0.84 | 0.07 | 7.55% |
| 2026-05-11 | 2026-03 | -0.91 | -0.98 | -0.07 | -7.69% |
| 2026-02-25 | 2025-12 | -0.92 | -0.92 | N/A | N/A |
| 2025-11-05 | 2025-09 | -0.89 | -1.1 | -0.21 | -23.60% |
| 2025-08-05 | 2025-06 | -0.73 | -0.87 | -0.14 | -19.18% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-01 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-06-09 | BTIG | Upgrade | Buy | Buy |
| 2026-06-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-12 | Needham | Upgrade | Buy | Buy |
Profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-21 | BODENSTEDT MATTHIAS | Chief Financial Officer | 1.12M | Sale |
| 2026-03-30 | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-09-29 | CHEN BIHUA X. | Former | 0.00 | Sale |
| 2025-07-02 | MOUKHEIBIR CATHERINE | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-07-26 | REICH KRISTIAN | Officer | 0.00 | Sale |
| 2026-07-09 | SANTOS DA SILVA JORGE | Chief Executive Officer | 2.77M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | BVF Inc. | 16.00M | 239.86M | 18.80% |
| 2026-06-29 | Deep Track Capital, Lp | 7.00M | 104.92M | 8.22% |
| 2026-06-29 | T. Rowe Price Investment Management, Inc. | 4.28M | 64.17M | 5.03% |
| 2026-06-29 | Shaw D.E. & Co., Inc. | 3.37M | 50.45M | 3.95% |
| 2026-06-29 | Cormorant Asset Management, LP | 3.21M | 48.05M | 3.77% |
| 2026-06-29 | Jupiter Topco LLC | 3.09M | 46.26M | 3.63% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 887.03K | 13.30M | 1.04% |
| 2026-06-29 | JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 350.13K | 5.25M | 0.41% |
| 2026-06-29 | T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 167.77K | 2.51M | 0.20% |
| 2026-05-30 | BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 161.39K | 2.42M | 0.19% |
| 2026-06-29 | Voya Investors TRT-VY(R) T. Rowe Price Capital Appreciation PORT. | 160.30K | 2.40M | 0.19% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 143.56K | 2.15M | 0.17% |